A national register for recommended dosages of medicinal products used in paediatrics is available to health professionals (Swisspeddose). Incentives are also introduced to encourage the pharmaceutical industry to develop paediatric medicinal products.
The federal government has recognised the need to improve safety and the use of medicinal products in children and new born babies.
The legal basis for such a register came into force in January 2018 in connection with the ordinary revision of the Therapeutic Products Act (TPA).
In September 2017 the FOPH commissioned the Swisspeddose Association to manage the register and continue the harmonisation work already carried out in a pilot project. At its meeting on 10 April 2019, the Federal Council decided to continue to contribute financially.
The Swisspeddose Association comprises the eight Swiss paediatric clinics, the Swiss Association for Paediatrics (SGP) and the Swiss Association of Public Health Administration and Hospital Pharmacists (GSASA).
Recommendations for dosages, indications and methods of administration for the active substances that are most commonly used in paediatrics have been published on the Swisspeddose website since April 2018. Health professionals have free access to the database. Dosage recommendations for more than 100 active substances used in paediatrics should be available by 2021.
Promoting the development of paediatric medicines
Efforts are under way globally to licence and bring to market more medicinal products suited for children. In the EU, legal provisions aimed at improving the offerings of medicinal products in paediatrics came into force on 26 January 2007.
To comply with EU legislation, the pharmaceutical industry has to provide also for Switzerland, when filing a licensing application for a new medicinal product at Swissmedic, additional data on safe and effective use in children.
Last modification 27.03.2020